Abstract
Tuberculosis (TB) with central nervous system (CNS) manifestation is a form of TB with a high mortality and morbidity. Tuberculous meningitis (TM) is the most common form of CNS-TB. Although diagnosis of CNS-TB can be challenging, early treatment of CNS-TB is related to a better outcome. If CNS-TB is suspected, even though the clinical picture is not specific, it should be immediately treated.
For the treatment of CNS-TB, knowledge of the penetration across the blood-brain barrier of the various antituberculosis agents used in TB treatment is important. These will be described here in order to serve as a guide in choosing a treatment for CNS-TB. Corticosteroids have an evidence-based value in the treatment of TM and so are recommended. As for thalidomide use in CNS-TB, sound evidence is still lacking. We will also include a description of the adverse neurotoxic effects of the various other agents including their psychiatric, ototoxic and ophthalmic adverse effects.
Keywords: Tuberculosis, central nervous system, tuberculous meningitis, antituberculosis agents, blood-brain barrier, corticosteroids, thalidomide, adverse neurotoxic effects, HIV infection, enzyme-linked immunospot assay (ELISpot assay)
Current Pharmaceutical Design
Title: Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Volume: 17 Issue: 27
Author(s): J. J. van der Harst and G. J. Luijckx
Affiliation:
Keywords: Tuberculosis, central nervous system, tuberculous meningitis, antituberculosis agents, blood-brain barrier, corticosteroids, thalidomide, adverse neurotoxic effects, HIV infection, enzyme-linked immunospot assay (ELISpot assay)
Abstract: Tuberculosis (TB) with central nervous system (CNS) manifestation is a form of TB with a high mortality and morbidity. Tuberculous meningitis (TM) is the most common form of CNS-TB. Although diagnosis of CNS-TB can be challenging, early treatment of CNS-TB is related to a better outcome. If CNS-TB is suspected, even though the clinical picture is not specific, it should be immediately treated.
For the treatment of CNS-TB, knowledge of the penetration across the blood-brain barrier of the various antituberculosis agents used in TB treatment is important. These will be described here in order to serve as a guide in choosing a treatment for CNS-TB. Corticosteroids have an evidence-based value in the treatment of TM and so are recommended. As for thalidomide use in CNS-TB, sound evidence is still lacking. We will also include a description of the adverse neurotoxic effects of the various other agents including their psychiatric, ototoxic and ophthalmic adverse effects.
Export Options
About this article
Cite this article as:
J. van der Harst J. and J. Luijckx G., Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470237
DOI https://dx.doi.org/10.2174/138161211797470237 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Recent Developments in Synthetic Oligosaccharide-Based Bacterial Vaccines
Current Topics in Medicinal Chemistry Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Transient Blood Brain Barrier Disruption Induced by Oleic Acid is Mediated by Nitric Oxide
Current Neurovascular Research Nanostructures as Promising Tools for Delivery of Antimicrobial Peptides
Mini-Reviews in Medicinal Chemistry Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy HIV-1, Methamphetamine and Astrocyte Glutamate Regulation: Combined Excitotoxic Implications for Neuro-AIDS
Current HIV Research Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery Computational Biology Tools for Identifying Specific Ligand Binding Residues for Novel Agrochemical and Drug Design
Current Protein & Peptide Science How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research Neurobrucellosis: A Case Report with an Unusual Presentation
Recent Advances in Anti-Infective Drug Discovery Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Genetics and Vaccines in the Era of Personalized Medicine
Current Genomics Ivermectin in Human Medicine, An Overview of the Current Status of Its Clinical Applications
Current Pharmaceutical Biotechnology <i>In Silico</i> Studies for Bacterystic Evaluation against <i>Staphylococcus aureus</i> of 2-Naphthoic Acid Analogues
Current Topics in Medicinal Chemistry Chemical Consequences of Radioactive Decay and their Biological Implications
Current Radiopharmaceuticals Brain Perfusion In Sepsis
Current Vascular Pharmacology Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents